Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Aug 13;8(15):4207-4208.
doi: 10.1182/bloodadvances.2024013427.

This differentiation block will not stand, man: ivosidenib for MDS

Ryan J Beechinor  1   2 , Brian A Jonas  3
Affiliations
Comment

This differentiation block will not stand, man: ivosidenib for MDS

Ryan J Beechinor et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: B.A.J. serves as a consultant/adviser for AbbVie, Bristol Myers Squibb (BMS), Daiichi Sankyo, Gilead, GlycoMimetics, Kymera, Kura, Rigel, Schrodinger, Syndax, and Treadwell; is on the protocol steering committee for GlycoMimetics; is on the data monitoring committee for Gilead; received travel reimbursement/support from Rigel; and received research funding to his institution from AbbVie, Amgen, Aptose Biosciences, AROG, Biomea Fusion, BMS, Celgene, F. Hoffmann-La Roche, Forma, Forty Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi Pharmaceutical, Immune-Onc Therapeutics, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, and Treadwell. R.J.B. received funding/compensation for consulting and/or research activities from the following entities: National Institutes of Health, Eunice Kennedy Shriver National Institute for Child Health and Human Development, Children’s Oncology Group, IQVIA, Cempra Pharmaceuticals, Oncology Reimbursement Management, Aptitude Health, The Dedham Group, Trinity Life Sciences, Academy of Managed Care Pharmacy, PRECISIONxtract, Deciphera Pharmaceuticals, and Pfizer Inc.

Comment on

References

    1. DiNardo CD, Roboz GJ, Watts JM, et al. Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Adv. 2024;8(15):4209–4220. - PubMed
    1. Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95(10):1668–1674. - PMC - PubMed
    1. Patnaik MM, Hanson CA, Hodnefield JM, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a mayo clinic study of 277 patients. Leukemia. 2012;26(1):101–105. - PubMed
    1. Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021;48 - PubMed
    1. Bewersdorf JP, Zeidan AM. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: what is on the horizon? Best Pract Res Clin Haematol. 2021;34(1) - PubMed

MeSH terms